Skip to main content

NewcelX Ltd.

corporate_fare Company Profile

NewcelX Ltd.

NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed NCEL - Latest Insights

NCEL
Apr 20, 2026, 7:40 AM EDT
Filing Type: 6-K
Importance Score:
8
NewcelX Advances Type 1 Diabetes Program with Eledon Collaboration, Targets Q1 2027 IND
Sentiment: Positive
View Wiseek Article
NCEL
Apr 01, 2026, 5:03 PM EDT
Filing Type: 6-K
Importance Score:
9
NewcelX Secures $1.35M Private Placement at 30% Premium, Bolstering Type 1 Diabetes Program
Sentiment: Positive
View Wiseek Article
NCEL
Mar 09, 2026, 7:21 AM EDT
Filing Type: 6-K
Importance Score:
8
NewcelX Partners with Eledon Pharmaceuticals to Accelerate NCEL-101 Program for Type 1 Diabetes
Sentiment: Positive
View Wiseek Article
NCEL
Mar 09, 2026, 7:20 AM EDT
Source: Reuters
Importance Score:
8
NewcelX Forms Strategic Alliance with Eledon to Advance NCEL-101 Diabetes Program
Sentiment: Positive
View Wiseek Article
NCEL
Feb 12, 2026, 7:13 AM EST
Filing Type: 6-K
Importance Score:
8
NewcelX Reports Peer-Reviewed Publication for Mazindol ER, Advances Monetization Discussions
Sentiment: Positive
View Wiseek Article
NCEL
Jan 29, 2026, 7:13 AM EST
Filing Type: 6-K
Importance Score:
7
NewcelX Updates Corporate Presentation, Reinforces Type 1 Diabetes Focus, and Expands Leadership Ahead of Key Conferences
Sentiment: Positive
View Wiseek Article
NCEL
Jan 12, 2026, 7:12 AM EST
Filing Type: 6-K
Importance Score:
7
NewcelX Reports Positive Collaborative Study Results for Islet Delivery in Type 1 Diabetes
Sentiment: Positive
View Wiseek Article
NCEL
Jan 05, 2026, 7:21 AM EST
Filing Type: 6-K
Importance Score:
7
NewcelX Appoints Big Pharma Diabetes Leader Dr. Julien Boisdron to Scientific Advisory Board
Sentiment: Positive
View Wiseek Article